trimethoprim: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Dr Reddys Labs Sa	TRIMETHOPRIM	trimethoprim	TABLET;ORAL	018679	NDA	Dr. Reddy's Labratories Inc.	75907-043-01	100 TABLET in 1 BOTTLE (75907-043-01)	2024-01-30
Novel Labs Inc	TRIMETHOPRIM	trimethoprim	TABLET;ORAL	091437	ANDA	Novel Laboratories, Inc.	40032-330-24	100 TABLET in 1 BOTTLE (40032-330-24)	2014-03-04
Novel Labs Inc	TRIMETHOPRIM	trimethoprim	TABLET;ORAL	091437	ANDA	Lupin Pharmaceuticals,Inc.	43386-330-01	100 TABLET in 1 BOTTLE (43386-330-01)	2011-06-24
Novitium Pharma	TRIMETHOPRIM	trimethoprim	TABLET;ORAL	216393	ANDA	Golden State Medical Supply, Inc.	51407-738-01	100 TABLET in 1 BOTTLE, PLASTIC (51407-738-01)	2022-10-28
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: May 25, 2026

Trimethoprim Suppliers: Who Manufactures the API, Intermediates, and Key Finished-Dose Products

Trimethoprim is a widely used antimicrobial active ingredient and is sold through a fragmented global supply base covering API, key intermediates, and finished-dose formulations (commonly tablets, capsules, oral solids, and fixed-dose combinations such as trimethoprim-sulfamethoxazole). The supplier landscape is dominated by large chemical-pharma API manufacturers in India, China, and parts of Europe, plus finished-dose and contracting manufacturers that source compliant trimethoprim API and build US- and EU-market tablets/capsules.

Below is a structured view of the supplier categories and where procurement risk concentrates for trimethoprim programs.

Who supplies trimethoprim API for finished-dose drug manufacturers?

Primary API supply pattern

Most finished-dose manufacturers source trimethoprim API rather than synthesizing in-house. Procurement typically spans:

US/EU compliant API supply chains for regulatory submissions
DMF holders for regulatory file access (US) and relevant registration/technical dossiers (EU where applicable)
Long-term framework agreements for stable supply due to tight upstream capacity at certain periods

Common upstream concentration points

Trimethoprim API supply is sensitive to:

availability of antibiotic-precursor chemical inputs
fermentation-free fine-chemical capacity (chemical synthesis steps)
regulatory audits at API sites (GMP, cross-contamination control, cleaning validation)

Which companies manufacture trimethoprim API (major global suppliers)?

Supplier set used in procurement

A typical procurement due-diligence shortlist for trimethoprim API includes API producers in:

India (large volume generic API capacity)
China (high-volume chemical API capacity and intermediates)
Europe (fewer total sites for older antibiotics but strong compliance where present)

Procurement-relevant supplier characteristics

For buyers, supplier qualification tends to focus on:

DMF status and ability to bridge submissions
CEP/CoC history (for Europe)
batch release consistency and impurity profile control
capacity and lead times (trimethoprim is not a high-flex margin product)

What trimethoprim intermediates and building blocks drive supplier availability?

Key intermediate dependency

Trimethoprim API production depends on specialty heterocycle chemistry and nitro/amine intermediate steps. Supplier risk usually tracks:

reliance on a small number of intermediate producers
transport and documentation for controlled intermediates
changes in impurity carryover from upstream intermediate lots

Contract manufacturing implications

Finished-dose CMOs typically require:

verified intermediate chain-of-custody from qualifying API suppliers
impurity specifications aligned to pharmacopeia and buyer NDA/ANDA requirements

What finished-dose manufacturers supply trimethoprim tablets and capsules?

Typical finished-dose sourcing

Finished-dose trimethoprim products are supplied by:

branded legacy manufacturers (where still marketed)
multiple generic finished-dose players for US and non-US markets
combination-product manufacturers for fixed-dose antimicrobial regimens

Most common commercial product forms

Oral tablets
Oral capsules
Combination tablets (trimethoprim-sulfamethoxazole, in varying strengths)

Which suppliers dominate trimethoprim-sulfamethoxazole (TMP-SMX) combination supply chains?

Why combination products matter

Trimethoprim alone is smaller volume than TMP-SMX in many markets. As a result, buyers for TMP-SMX often lock supplier networks that cover both:

trimethoprim API
sulfamethoxazole API
blend and uniformity controls for fixed-dose dosing

Procurement lens

When buying through contract manufacturers, TMP-SMX supply risk concentrates in:

co-sourced API availability at the same quality standard
co-milling/blending performance for tablet uniformity
impurity control across both APIs

How many trimethoprim API DMF holders exist in the US and how does that affect procurement?

DMF access drives speed

For US launch and lifecycle management, buyers often prefer API suppliers with:

active DMF support
established cross-reference or bridging packages for filings
documented batch history matching buyer impurity acceptance limits

Procurement effect

A larger DMF holder set reduces procurement lead-time risk, but increases the need for:

DMF equivalency checks
change control review and comparability packages
supplier audit scheduling

What is the regulatory status of trimethoprim suppliers for FDA and EU markets?

US (FDA) compliance expectations

Trimethoprim API suppliers supplying US-market finished-dose manufacturers typically need:

GMP compliance at manufacturing sites
DMF or controlled access where required for application support
consistent impurity profiles aligned to required specifications

EU (EMA/UK) compliance expectations

EU buyers typically evaluate:

GMP compliance (including site inspections)
registration/technical dossier status where applicable
ability to supply within approved quality frameworks

How strong are the patent and regulatory barriers that affect trimethoprim sourcing?

Patent landscape practical impact

Trimethoprim is an established generic antimicrobial. For procurement planning, the major barriers are usually not composition-of-matter exclusivities, but:

regulatory documentation requirements
quality system maturity
audit readiness and change control discipline

What matters operationally

API specification conformance
batch-to-batch reproducibility
ability to support regulatory filing lifecycle changes

What generic entry risks exist for trimethoprim products that depend on supplier access?

Supply-side entry risk

Generic entry risk for trimethoprim is less about API patent blocking and more about:

securing compliant API lots for bioequivalence and stability
ensuring impurity controls meet dossier criteria
managing change control during scale-up

Commercial timing risk

If the buyer can’t secure consistent trimethoprim API supply, timelines slip for:

formulation finalization
BE/clinical comparability packages
batch release and validation schedules

How do trimethoprim supplier networks differ by geography (US vs EU vs ROW)?

US sourcing

US-oriented supply chains emphasize:

DMF-supported documentation
inspection and audit history
predictable release timelines

EU sourcing

EU oriented chains emphasize:

site GMP inspection performance
technical dossier readiness and quality documentation
stability and pharmacopeia conformity across batch series

ROW sourcing

ROW markets often prioritize:

cost and availability
local regulatory dossier compliance pathways
lead-time predictability

Supplier due diligence checklist for trimethoprim (API and finished dose)

Quality and documentation

GMP certificate for the trimethoprim API site
DMF access status and cross-reference feasibility (US)
impurity and polymorph controls (where applicable)
CoA templates matching specifications
stability protocol alignment to buyer dossier needs

Operations and risk

validated cleaning and cross-contamination controls
batch traceability and deviation/CAPA history
capacity commitment terms and lead times
change control notice periods and comparability plan support

Commercial and regulatory resilience

second-source qualification speed
ability to supply during peak regulatory cycles
audit schedule readiness and responsiveness

Key Takeaways

Trimethoprim procurement is driven by API supply chain qualification, not by active innovation exclusivity.
The most meaningful supplier decision points are DMF/documentation readiness (US), GMP audit performance, impurity control consistency, and change-control discipline.
For combination products (TMP-SMX), supply risk concentrates in co-sourcing both APIs to the same quality and release timelines.
Buyers should structure procurement around audit-ready, documentation-supported suppliers with demonstrated batch consistency and validated manufacturing controls.

FAQs

1) How do I qualify a new trimethoprim API supplier for an ANDA?

Qualification centers on GMP status, impurity/spec conformity, DMF access (or bridging documentation), and ability to support change-control and comparability for lifecycle management.

2) What specifications matter most for trimethoprim API quality?

Focus on identity/purity acceptance criteria, related impurities, residual solvents (where relevant), assay, and stability-consistent behavior tied to the buyer’s approved specification set.

3) Are there common batch inconsistency drivers for trimethoprim API?

Drivers typically include upstream intermediate variability, impurity carryover, and deviations during fine-chemical synthesis steps.

4) Does trimethoprim supply risk spike seasonally?

Risk can spike around audit cycles, upstream intermediate procurement lead times, and regional inspection backlogs that slow release.

5) What is the best approach to mitigate trimethoprim supply disruption?

Maintain at least one qualified secondary supplier and contract terms that preserve lead-time continuity for API release and formulation production scheduling.

References

FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration.
FDA. DMF (Drug Master File) program overview and guidance materials. U.S. Food and Drug Administration.
EMA. GMP and quality guidance related to active substance manufacturing. European Medicines Agency.